Évaluation de l'impact de la mutation de résistance à l'oseltamivir (H275Y) sur les capacités réplicatives et la virulence du virus pandémique A(H1N1) pdm09
|Authors:||Pinilla, Lady Tatiana|
|Advisor:||Abed, Yacine; Boivin, Guy|
|Abstract:||One class of anti-influenza agents; the neuraminidases inhibitors (NAIs), is the only choice commercially available for treatment and prophylaxis of seasonal and pandemic influenza infections. The pandemic 2009 Influenza virus, A(H1N1)pdm09, was naturally resistant to adamantanes but susceptible to the NAI: oseltamivir and zanamivir. However, more than 1.5% of cases of oseltamivir resistance have been reported during treatment and prophylaxis and most of them carried a single nucleotide mutation (cytosine to thymidine) at position 823 that resulted in a histidine to tyrosine mutation at position 275 in the neuraminidase sequence (H275Y). Considering that the number of available anti-influenza drugs is very restricted (zanamivir is now the only commercially available drug for treatment of the adamantane- and oseltamivir-resistant A(H1N1)pdm09 strains), it is important to understand mechanisms of resistance to NAIs and to perform a surveillance program for evolution of such drug-resistant variants.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||19 April 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.